Journal: Seminars in respiratory and critical care medicine
This publication reviews the evolving management of stage I to III non-small cell lung cancer (NSCLC), focusing on advances in immunotherapy and targeted treatments for resectable disease.
Key highlights include:
- CheckMate 816 trial: Demonstrated improved survival with neoadjuvant chemoimmunotherapy.
- Adjuvant targeted agents: Benefits of osimertinib and alectinib for patients with EGFR and ALK alterations.
The review also covers updated diagnostic strategies and multidisciplinary treatment approaches.
Challenges discussed include:
- Optimal therapy sequencing
- Patient selection
- Treatment duration
Personalized multimodal treatment based on molecular and clinical features is emphasized as essential for improving long-term outcomes.